What is William Blair’s Estimate for Nkarta Q1 Earnings?

Nkarta, Inc. (NASDAQ:NKTX) – William Blair issued their Q1 2026 EPS estimates for shares of Nkarta in a report released on Tuesday, November 11th. William Blair analyst S. Corwin forecasts that the company will earn ($0.32) per share for the quarter. The consensus estimate for Nkarta’s current full-year earnings is ($1.70) per share. William Blair also issued estimates for Nkarta’s Q2 2026 earnings at ($0.32) EPS, Q3 2026 earnings at ($0.33) EPS and Q4 2026 earnings at ($0.33) EPS.

A number of other equities research analysts have also issued reports on the company. Needham & Company LLC reissued a “buy” rating and set a $10.00 price target on shares of Nkarta in a research note on Wednesday, August 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nkarta in a research report on Friday, October 31st. Stifel Nicolaus lowered their target price on shares of Nkarta from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Tuesday. Finally, Wall Street Zen raised shares of Nkarta from a “sell” rating to a “hold” rating in a research note on Saturday, October 25th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $13.25.

Nkarta Price Performance

Shares of NASDAQ NKTX opened at $2.01 on Wednesday. Nkarta has a 1 year low of $1.31 and a 1 year high of $3.40. The firm has a 50-day simple moving average of $2.14 and a two-hundred day simple moving average of $2.01. The company has a market cap of $142.77 million, a P/E ratio of -1.46 and a beta of 0.86.

Nkarta (NASDAQ:NKTX) last announced its earnings results on Monday, November 10th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.03.

Hedge Funds Weigh In On Nkarta

Institutional investors have recently bought and sold shares of the business. Savant Capital LLC purchased a new stake in Nkarta during the second quarter worth $36,000. SG Americas Securities LLC increased its holdings in shares of Nkarta by 35.0% in the 3rd quarter. SG Americas Securities LLC now owns 23,663 shares of the company’s stock valued at $49,000 after acquiring an additional 6,141 shares during the period. CWM LLC raised its position in shares of Nkarta by 3,437.3% in the 1st quarter. CWM LLC now owns 28,157 shares of the company’s stock worth $52,000 after acquiring an additional 27,361 shares in the last quarter. Cerity Partners LLC purchased a new stake in shares of Nkarta during the 1st quarter worth $55,000. Finally, Bailard Inc. purchased a new stake in shares of Nkarta during the 3rd quarter worth $61,000. 80.54% of the stock is owned by hedge funds and other institutional investors.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.